U.S. stock night trading fluctuations: Amgen rose 3.07% in night trading, boosted by low valuation and the attractiveness of its oncology business

U.S. Stock Night Market Movements

Amgen rose 3.07% in the night market. Based on recent news,

1. On July 14, market analysts pointed out that although Amgen is currently rated as hold, top analysts believe there are five stocks that are more worthy of purchase. This news may lead some investors to reassess their portfolios, driving up the stock price.

2. On July 16, Citigroup analyst Geoff Meacham maintained a hold rating on Amgen and set a target price of $345. At the same time, Wells Fargo's Mohit Bansal also maintained a hold rating in a report released on July 13, while Bank of America Securities reiterated a sell rating on Amgen. The differing opinions among analysts may trigger market volatility.

3. On July 14, investors focused on Amgen's growth prospects. Despite the drag from biosimilars, if input costs remain volatile and Most Favored Nation pricing tightens, Amgen's lower price-to-earnings ratio and operational oncology business become more attractive on a relative basis. Investor reactions to these factors may drive up the stock price. There are discrepancies in market analysts' ratings on Amgen, and investors should exercise caution.

Top Stocks by Industry Trading Volume

BeiGene fell 2.34% in the night market. Based on recent key news:

1. On July 14, BeiGene CEO John Oyler sold 145,861 shares of the company, with a transaction amount of $44,626,424. This move may raise market concerns about internal confidence in the company, leading to a drop in stock price.

2. No other significant news recently. The market is sensitive to executives selling shares.

Gilead Sciences rose 1.22% in the night market. Based on recent key news:

1. On July 16, Gilead Sciences announced that it would adjust the ratio of underlying assets to BDRs in its BDR program in Brazil and conduct a mandatory stock split. This change may lead to increased market demand for the company's stock, driving up the stock price. Source: Public Technologies

2. On July 15, Gilead Sciences acquired Ouro Medicines for $2.175 billion. This acquisition may enhance Gilead's product line and market competitiveness, boosting investor confidence. Source: Connoa Enterprises Announcement

3. On July 16, Gilead Sciences donated 2,400 bottles of obeldesivir and 2,000 bottles of remdesivir to support trials. This initiative may enhance the company's reputation in public health, thereby affecting the stock price. Source: Public Technologies The pharmaceutical industry is driven by innovation, attracting high market attention.

Moderna fell 1.84% in the night market. Based on recent key news:

1. On July 16, Moderna launched a Phase I trial of mRNA-4200 in the U.S., aimed at assessing its safety and tolerability in patients with solid tumors. This news failed to boost market confidence, leading to a drop in stock price

2. On July 16, Arbutus Biopharma announced a settlement agreement with Moderna, with Moderna paying $178 million. Although the settlement helps eliminate legal uncertainty, it failed to stop the decline in stock prices.

3. On July 15, Arbutus Biopharma terminated its RSV agreement with Genevant, involving Moderna's mRESVIA vaccine. The termination of the agreement may raise market concerns about Moderna's future partnerships, affecting stock prices. The biotechnology industry has recently faced patent litigation risks